PriceTargets.com logo

Beauty Health - SKIN Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $6.50
  • Forecasted Upside: 112.42%
  • Number of Analysts: 12
  • Breakdown:
  • 3 Sell Ratings
  • 7 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.06 As of 04/25/2024 01:00 AM ET
▼ -0.09 (-2.86%)

This chart shows the closing price for SKIN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Beauty Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SKIN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SKIN

Analyst Price Target is $6.50
▲ +112.42% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Beauty Health in the last 3 months. The average price target is $6.50, with a high forecast of $23.00 and a low forecast of $2.50. The average price target represents a 112.42% upside from the last price of $3.06.

This chart shows the closing price for SKIN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 12 investment analysts is to reduce stock in Beauty Health. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2024DA DavidsonReiterated RatingBuy ➝ Buy$5.00N/A
3/14/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$3.00 ➝ $4.00Low
3/13/2024TD CowenBoost TargetMarket Perform ➝ Market Perform$2.50 ➝ $4.00Low
3/13/2024Stifel NicolausReiterated RatingHold ➝ Hold$3.00 ➝ $4.00Low
3/13/2024Piper SandlerReiterated RatingUnderweight ➝ Underweight$2.00 ➝ $3.00Low
2/29/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$2.50 ➝ $3.00Low
11/15/2023Jefferies Financial GroupDowngradeBuy ➝ HoldLow
11/14/2023Stifel NicolausLower TargetHold ➝ Hold$8.00 ➝ $3.00Low
11/14/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$10.00 ➝ $2.50Low
11/14/2023JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
11/14/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$10.00 ➝ $2.50Low
11/14/2023Piper SandlerDowngradeOverweight ➝ Underweight$12.00 ➝ $2.00Low
11/14/2023TD CowenDowngradeOutperform ➝ Market Perform$9.00 ➝ $2.50Low
11/14/2023BenchmarkDowngradeBuy ➝ HoldLow
11/14/2023Raymond JamesDowngradeMarket Perform ➝ UnderperformLow
11/14/2023William BlairDowngradeOutperform ➝ Market PerformLow
9/19/2023Imperial CapitalInitiated CoverageOutperformLow
9/13/2023BenchmarkReiterated RatingBuy ➝ Buy$23.00Low
8/25/2023Canaccord Genuity GroupReiterated RatingBuy$10.00Low
8/10/2023TD CowenLower TargetOutperform ➝ Outperform$15.00 ➝ $9.00Low
8/10/2023DA DavidsonLower TargetBuy ➝ Buy$35.00 ➝ $16.50N/A
8/8/2023BenchmarkReiterated RatingBuy ➝ Buy$23.00Low
6/20/2023Stifel NicolausDowngradeBuy ➝ Hold$17.00 ➝ $10.00Low
6/15/2023Piper SandlerLower Target$17.00 ➝ $15.00Low
3/28/2023Canaccord Genuity GroupReiterated RatingBuy$18.00Low
3/20/2023BNP ParibasUpgradeUnderperform ➝ NeutralLow
3/14/2023BenchmarkReiterated RatingBuy$23.00Low
3/1/2023DA DavidsonBoost TargetBuy$32.00 ➝ $35.00Low
2/28/2023BenchmarkReiterated RatingBuy$23.00Low
2/16/2023CowenLower TargetOutperform$20.00 ➝ $15.00Low
12/16/2022Piper SandlerLower Target$16.00 ➝ $15.00Low
11/23/2022The Goldman Sachs GroupLower TargetBuy$22.00 ➝ $19.00Low
11/15/2022DA DavidsonBoost Target$32.00Low
11/9/2022DA DavidsonBoost TargetBuy$31.00 ➝ $32.00Low
11/9/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$22.00 ➝ $11.00Low
9/28/2022DA DavidsonBoost TargetBuy$30.00 ➝ $31.00Low
9/16/2022JPMorgan Chase & Co.Boost Target$18.00 ➝ $22.00Low
9/16/2022Piper SandlerBoost TargetOverweight$20.00 ➝ $23.00Low
9/16/2022DA DavidsonBoost TargetBuy$25.00 ➝ $30.00Low
8/16/2022The Goldman Sachs GroupLower TargetBuy$25.00 ➝ $22.00Low
8/10/2022Piper SandlerLower TargetOverweight$22.00 ➝ $20.00Low
8/10/2022DA DavidsonBoost TargetBuy$24.00 ➝ $25.00Low
7/8/2022Piper SandlerLower TargetOverweight$24.00 ➝ $22.00N/A
6/30/2022Canaccord Genuity GroupLower Target$22.00 ➝ $20.00Low
5/11/2022Canaccord Genuity GroupLower Target$27.00 ➝ $22.00High
5/11/2022DA DavidsonLower Target$35.00 ➝ $24.00High
5/11/2022Piper SandlerLower Target$26.00 ➝ $24.00High
4/28/2022Piper SandlerLower Target$31.00 ➝ $26.00Medium
3/14/2022BenchmarkBoost TargetBuy$18.00 ➝ $23.00High
3/11/2022JPMorgan Chase & Co.Initiated CoverageOverweight$24.00High
2/23/2022DA DavidsonBoost TargetBuy$32.00 ➝ $35.00High
1/7/2022William BlairInitiated CoverageOutperformMedium
12/23/2021Raymond JamesInitiated CoverageMarket PerformMedium
11/10/2021DA DavidsonBoost TargetBuy$26.00 ➝ $32.00High
10/7/2021Stifel NicolausInitiated CoverageBuy$33.00High
10/4/2021CowenInitiated CoverageOutperform$32.00Medium
9/1/2021Piper SandlerBoost TargetSell ➝ Overweight$27.00 ➝ $33.00High
8/11/2021DA DavidsonBoost TargetBuy$17.50 ➝ $26.00High
8/11/2021BenchmarkBoost TargetBuy$18.00 ➝ $25.00High
7/19/2021Jefferies Financial GroupInitiated CoverageBuy$22.00High
7/1/2021The Goldman Sachs GroupInitiated CoverageBuy$31.00High
6/28/2021BenchmarkBoost TargetBuy$16.00 ➝ $22.00Low
6/24/2021Piper SandlerInitiated CoverageOverweight$24.00Medium
6/1/2021DA DavidsonBoost TargetBuy$16.00 ➝ $17.50High
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.92 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 68 very positive mentions
  • 34 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 57 very positive mentions
  • 34 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
10/29/2023
  • 84 very positive mentions
  • 40 positive mentions
  • 8 negative mentions
  • 4 very negative mentions
Mentions as of
11/28/2023
  • 68 very positive mentions
  • 41 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 71 very positive mentions
  • 50 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 47 very positive mentions
  • 36 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
2/26/2024
  • 74 very positive mentions
  • 37 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
3/27/2024
  • 62 very positive mentions
  • 42 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 62 very positive mentions
  • 42 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Beauty Health logo
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Read More

Today's Range

Now: $3.06
Low: $2.94
High: $3.13

50 Day Range

MA: $3.65
Low: $2.80
High: $4.53

52 Week Range

Now: $3.06
Low: $1.35
High: $11.82

Volume

2,494,945 shs

Average Volume

1,417,538 shs

Market Capitalization

$377.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Beauty Health?

The following Wall Street research analysts have issued research reports on Beauty Health in the last twelve months: Benchmark Co., Canaccord Genuity Group Inc., DA Davidson, Imperial Capital, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Raymond James, Stifel Nicolaus, TD Cowen, and William Blair.
View the latest analyst ratings for SKIN.

What is the current price target for Beauty Health?

7 Wall Street analysts have set twelve-month price targets for Beauty Health in the last year. Their average twelve-month price target is $6.50, suggesting a possible upside of 112.4%. Benchmark Co. has the highest price target set, predicting SKIN will reach $23.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $2.50 for Beauty Health in the next year.
View the latest price targets for SKIN.

What is the current consensus analyst rating for Beauty Health?

Beauty Health currently has 3 sell ratings, 7 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for SKIN.

What other companies compete with Beauty Health?

Other companies that are similar to Beauty Health include Surmodics, Anika Therapeutics, Pulse Biosciences, OraSure Technologies and NeuroPace. Learn More about companies similar to Beauty Health.

How do I contact Beauty Health's investor relations team?

Beauty Health's physical mailing address is 1819 West Avenue Bay 2, Miami Beach FL, 33139. The company's listed phone number is 800-603-4996 and its investor relations email address is https://investors.beautyhealth.com. The official website for Beauty Health is hydrafacial.com. Learn More about contacing Beauty Health investor relations.